Los Angeles Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Los Angeles Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-85,805	Closed	-$415K	–	1548
2020 Q1	$415K	Buy	85,805 +48,470	+130%	+$314K	﹤0.01%	964
2019 Q4	$397K	Buy	37,335 +4,630	+14%	+$46K	﹤0.01%	1069
2019 Q3	$340K	Buy	32,705 +21,540	+193%	+$282K	﹤0.01%	1095
2019 Q2	$171K	Hold	11,165	–	–	﹤0.01%	1301
2019 Q1	$143K	Sell	11,165 -2,160	-16%	-$24.4K	﹤0.01%	1327
2018 Q4	$127K	Sell	13,325 -175	-1%	-$2.27K	﹤0.01%	1233
2018 Q3	$224K	Sell	13,500 -11,320	-46%	-$181K	﹤0.01%	1306
2018 Q2	$398K	Buy	+24,820	New	+$443K	﹤0.01%	1200

Los Angeles Capital Management's STML Position: Q2 2020 in Review

Los Angeles Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 85,805 shares — an estimated $415K sold.

Los Angeles Capital Management first reported a position in STML in Q2 2018 and held it in 8 quarters. The position peaked at $415K in Q1 2020. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Los Angeles Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Los Angeles Capital Management sold 85,805 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $415K.
Los Angeles Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 8 quarters.
Los Angeles Capital Management's Stemline Therapeutics, Inc. position peaked at $415K in Q1 2020.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Los Angeles Capital Management's 13F filing for Q2 2020, filed 5 Aug 2020.